Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)
MESH
Outcomes of Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma; Middle Meningeal Artery Embolization for Chronic Subdural Hematoma (MESH)
1 other identifier
observational
5,000
3 countries
19
Brief Summary
This multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with MMAE, including clinical effectiveness, recurrence rates, and safety profile.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2023
Typical duration for all trials
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 5, 2023
CompletedStudy Start
First participant enrolled
December 5, 2023
CompletedFirst Posted
Study publicly available on registry
December 26, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2026
January 7, 2026
January 1, 2026
2.7 years
December 5, 2023
January 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Reaccumulation of Hematoma
The percentage of patients who were determined to have a reaccumulation of their hematoma will be tabulated and reported
Within 1 month post MMAE
Rescue surgical evacuation
The percentage of patients who were determined to require rescue surgical evacuation of their hematoma will be tabulated and reported
Between 1-3 months post MMAE
Secondary Outcomes (17)
Reaccumulation of Hematoma
Between 1-3 months post MMAE
Reaccumulation of Hematoma
Between 3-6 months post MMAE
Reaccumulation of Hematoma
Between 6-12 months post MMAE
Reaccumulation of Hematoma
Between 12-24 months post MMAE
Clinical Outcome at Follow-up Clinical outcome at follow-up
Upon study discharge, 1-4 weeks
- +12 more secondary outcomes
Eligibility Criteria
Patients with chronic subdural hematoma
You may qualify if:
- Consecutive adult patients (18 yrs. of age or older)
- Endovascular embolization of middle meningeal artery using any embolization material:
- PVA particles; Onyx, nBCA glue; dimethyl sulfoxide, microcoils, PVA with microcoils
You may not qualify if:
- Endovascular embolization of middle meningeal artery using any other embolization material
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Montefiore Medical Centerlead
- Geisinger Cliniccollaborator
- Heidelberg Universitycollaborator
- Henri Mondor University Hospitalcollaborator
- Ospedale Policlinico San Martinocollaborator
- Ospedale San Raffaelecollaborator
- Lehigh Valley Hospitalcollaborator
- Mayo Cliniccollaborator
- Medical University of South Carolinacollaborator
- New York Universitycollaborator
- Oregon Health and Science Universitycollaborator
- Sisters of Mercy University Hospitalcollaborator
- Unity Health Torontocollaborator
- Sutter Healthcollaborator
- University of Iowacollaborator
- Thomas Jefferson Universitycollaborator
- University Health Network, Torontocollaborator
- University Hospital, Bordeauxcollaborator
- University of Alabama at Birminghamcollaborator
- University of South Floridacollaborator
- University of Washingtoncollaborator
- Cornell Universitycollaborator
- Westchester Medical Centercollaborator
Study Sites (19)
Baptist Health South Florida, Inc.
Coral Gables, Florida, 33143, United States
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
Orlando Regional Medical Center
Orlando, Florida, 32806, United States
University of Illinois Chicago
Chicago, Illinois, 60607, United States
University of Chicago Medicine
Chicago, Illinois, 60637, United States
The University of Iowa
Iowa City, Iowa, 52242, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Beth Israel Deaconess Medical Center (BIDMC)/Harvard Medical School
Boston, Massachusetts, 02215, United States
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Montefiore Medical Center
The Bronx, New York, 10467, United States
Geisinger Health
Danville, Pennsylvania, 17822, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, 19144, United States
UTHealth Houston
Houston, Texas, 77030, United States
HCA Houston Healthcare Kingwood
Kingwood, Texas, 77339, United States
Austin Health
Heidelberg, Victoria, 3084, Australia
Unity Health Toronto
Toronto, Ontario, M5C 2T2, Canada
University of Toronto
Toronto, Ontario, M5S 1A1, Canada
Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David Altschul, MD
Montefiore Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 5, 2023
First Posted
December 26, 2023
Study Start
December 5, 2023
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
August 1, 2026
Last Updated
January 7, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share